The 14-3-3 proteins are a family of phosphoserine/phosphothreonine-binding molecules that control the function of a wide array of cellular proteins. We suggest that one function of 14-3-3 is to support cell survival. 14-3-3 proteins promote survival in part by antagonizing the activity of associated proapoptotic proteins, including Bad
Introduction
14-3-3 proteins can bind a variety of proteins that are critical mediators of intracellular signalling pathways [ 1, 2] . Through protein-protein interactions, 14-3-3 participates in the regulation of diverse cellular processes, including cell proliferation and cell-cycle checkpoint control. Recent work on the interaction of 14-3-3 with deathpromoting proteins illustrates an important role of 14-3-3 in promoting cell survival signalling and preventing cell death. Because anti-neoplastic therapies ultimately eliminate tumour cells by the induction of apoptosis, understanding how 14-3-3-mediated survival pathways inhibit apoptosis may allow the use of 14-3-3 antagonists to sensitize tumour cells for effective therapy.
14-3-3 supports cell survival by inhibiting multiple death-promoting pathways
Apoptosis is a conserved, active process of cell death that plays a critical role in normal development, maintenance of tissue homoeostasis and elimination of damaged or unwanted cells [3-51. It is clear that cell death pathways are tightly associated with cell survival pathways to ensure that cell death occurs only when needed [5] . For example, the proapoptotic function of Bad, a Bcl-2 family member, can be inhibited by multiple kinases, including Akt/protein kinase B (PKB) and ribosomal S6 kinase (RSK), in response to a variety of survival signals.
T h e first indication that 14-3-3 is involved in regulation of cell death came when 14-3-3 was found to be associated with Bad in response to the survival factor interleukin-3 [6] , resulting in the inhibition of Bad proapoptotic activity. Greenberg and colleagues later discovered that 14-3-3-Bad association is regulated by Akt/PKB through phosphorylation of Bad, providing a direct link between a survival signalling kinase and a death promoter [7] . Bad contains three known phosphorylation sites, , and a host of kinases, including PKA, p21-activated kinase ('PAK') and RSK, have been shown to phosphorylate one or more of them . Although all three phosphorylation sites have been reported to be important for 14-3-3 binding, our studies demonstrate that 14-3-3-Bad interaction is strictly dependent on phosphorylated . Consistent with our conclusion, the death caused by wild-type Bad and Bad containing the S112A mutation, but not that caused by S136A Bad, could be profoundly inhibited by 14-3-3 overexpression. There are seven characterized 14-3-3 isoforms, all of which are capable of inhibiting Bad-induced apoptosis [15] .
These results suggest a critical role of 14-3-3 in prosurvival-kinase-mediated inhibition of Bad. It is possible that, upon activation, these kinases mark Bad for 14-3-3 binding by phosphorylating Ser-136. 14-3-3 can then exert its inhibitory effect on Bad proapoptotic activity.
Evidence is accumulating that 14-3-3 can act in a similar fashion to inhibit cell death caused by other death promoters, such as apoptosis signalregulating kinase 1 (ASKl). A S K l is a 150 kDa Ser/Thr kinase which was discovered as a mitogen-activated protein kinase kinase kinase with proapoptotic activity [16] . ASKl is a pivotal component of a signalling pathway induced by multiple death stimuli, including tumour necrosis factor a, Fas ligand, oxidative stress and the chemotherapeutic agents cisplatin and paclitaxel . Consistent with this model, ASKl-'-embryonic fibroblasts are resistant to tumour necrosis factor a-and H,O,-induced apoptosis [20] . We have established that 14-3-3 specifically interacts with ASKl through a phosphoserine motif at . T o test the role of this binding, we examined the effect of disrupting ASK1-14-3-3 interaction on ASK1-induced cell death. Expression of ASKlS96'A, a 14-3-3-binding-defective mutant, drastically increased the level of apoptosis seen in HeLa, COS-7 and HEK-293 cells in comparison to ASKlWT. This suggests that association with 14-3-3 inhibits the death-promoting activity of A S K l . T o directly test whether 14-3-3 can inhibit the proapoptotic activity of A S K l , we monitored ASKl -induced cell death in the presence of transiently expressed 14-3-3 (. Indeed, overexpression of 14-3-3 blocked ASKl"', but not ASKl"6iA, -induced apoptosis. Interestingly, co-expression of a ligandbinding-defective mutant of 14-3-3 (, K49E, did not inhibit ASKl -induced cell death, but instead promoted it. These data imply that this 14-3-3 mutant interferes with the function of endogenous 14-3-3 proteins, exhibiting a dominant negative effect. Another 14-3-3 mutant protein, R56/60E, has been shown to accelerate apoptosis induced by UV irradiation or serum withdrawal [22] . These data confirm a critical role of 14-3-3 in controlling the death-promoting activity of A S K l . This suggests another mechanism by which prosurvival kinases can engage 14-3-3 to block apoptosis. Thus regulation of ASKl by both proapoptotic and anti-apoptotic signals may provide a critical point of control for cell death and cell survival.
Inhibition of both Bad-and ASK1-induced apoptosis by 14-3-3 lends weight to the possibility Biochemical Society Transactions (2002) Volume 30, part 4 that 14-3-3 may have a general anti-apoptotic function. In support of this notion, 14-3-3 proteins also target many other proteins that are intimately involved in the regulation of apoptosis, including F K H R L l (a member of the forkhead family of transcription factors), insulin-like growth factor-I receptor (' IGFIR'), phosphoinositide 3-kinase and A20 [23-281.
14-3-3 employs a conserved groove for ligand binding, providing a target for pharmacological intervention
Using a combination of structural biology and genetic approaches, we have identified the primary protein-interaction site of 14-3-3 involved in ligand binding. In collaboration with Robert Liddington's laboratory, we solved the structure of 14-3-3 4 and postulated that an amphipathic groove in each 14-3-3 monomer, which is conserved among all 14-3-3 proteins, is the primary binding site for diverse ligands [29] . Mutational analysis of residues in this groove provided strong support for this model [30-321. Crystal structures of 14-3-3 in complex with phosphorylated peptides derived from middle T antigen ('MT') and 34] , with arylalkylamine Nacetyltransferase [35] , and with a non-phosphorylated peptide, R18 [33] , confirmed that the amphipathic groove of 14-3-3 is its main ligandbinding domain. Therefore, this conserved groove of 14-3-3 provides a specific target for disruption of 14-3-3-ligand interactions.
14-3-3 antagonists can disrupt I 4-3-3-ligand interactions in vitro and in vivo
T o control 14-3-3-ligand interactions, we desired a peptide antagonist of 14-3-3 proteins. In col-
Figure I
Crystal structural models of a 14-3-3 6 monomer bound to phosphorylated (pS-Raf-259) and nonphosphorylated (R18) ligands pS marks the phosphoserine in pS-Raf-259, while D and E mark the functionally equivalent residues in RI 8. Because R18 binds 14-3-3 without prior phosphorylation, it can be expressed in cells to inhibit 14-3-3-ligand interactions, a significant advantage over most other 14-3-3-binding peptides. T o increase the affinity of this peptide, we generated a dimeric R18 connected by a peptide linker, termed difopein (dimeric fourteen-three-three peptide -inhibitor) [38] . T o determine whether difopein can bind 14-3-3 in cells, an immunoprecipitation assay was used. 14-3-3 precipitates contained enhanced yellow fluorescent protein (EYFP)-difopein, but not EYFP (Figure 2 ). Significantly, expression of EYFP-difopein effectively dissociates 14-3-3 from its ligands, such as Raf-1 (Figure 2 ) . Thus it is likely that difopein can disrupt many, if not all, of the 14-3-3-ligand interactions that occur in cells, making it a valuable reagent to probe the function of 14-3-3 in many physiological processes.
Disruption of 14-3-3-ligand interactions leads to apoptotic cell death
T h e ability of 14-3-3 to inhibit several proapoptotic proteins while enhancing the function of prosurvival proteins supports the idea that 14-3-3 acts to promote cell survival. If this hypothesis is correct, blockade of 14-3-3-ligand binding would be expected to induce apoptosis. We have examined multiple markers of viability and apoptosis in COS-7 cells expressing R18 or difopein to address this issue. Upon expression of EYFPdifopein, the levels of activated caspase 3 increase, as determined using the substrate acetyl-DEVDp-nitroaniline. This effect is not mediated by
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Figure 2 Difopein can bind 14-3-3 and inhibit endogenous 14-3-3-ligand interactions HEK-293 cells were transfected with DNA coding for FLAG-14-3-3 and either EYFP or EYFPdifopein as indicated 14-3-3 was immunoprecipitated using anti-FLAG (M2) The presence of vanous species in the lysates and precipitated complexes was determined by Western blot using anti-Raf-I (top), anti-green fluorescent protein (GFP, middle) and anti-14-3-3 (bottom) antibodies The anti-GFP antibody recognizes GFP. enhanced GFP, enhanced cyan fluorescent protein ('ECFP') and EYFP equally well -+ + -+ + Figure 3 ). In addition, difopein A concern with the interpretation of these results is the possibility that R18 or difopein may have effects on proteins other than 14-3-3. T o address this issue, we tested the 14-3-3-bindingdefective mutant peptide R18(D12K, E14K) and found that it could not induce apoptosis. Thus the epitope of R18 responsible for induction of apoptosis overlaps the 14-3-3-binding domain, supporting the idea that R18 kills cells by inhibiting 14-3-3. We have also tested another 14-3-3 inhibitor peptide, C54, derived from Pseudomonas aeruginosa exoenzyme S [39] , which shares no sequence homology with R18, and have shown that it can cause apoptosis. These data support an essential role of 14-3-3 in transmission of survival signals.
I 4-3-3-mediated survival signalling acts upstream of the mitochondrial death machinery
It is believed that apoptosis signalling uses two major pathways, mitochondria-dependent and mitochondria-independent, that converge on the downstream effector caspases [3, 4] . T o place 14-3-3 among other known death regulators, we tested the effect of overexpression or inhibition of several regulators on EYFP-difopein-induced apoptosis. We found that the pan-caspase inhibitor zVAD-fmk (benzyloxycarbonyl-Val-Ala-DL-Aspfluoromethylketone) abolished the ability of EYFP-difopein to kill cells, which is consistent with the ability of difopein to activate caspase 3. This suggests that disruption of 14-3-3-ligand interactions causes cell death in an effectorcaspase-dependent manner. The Bcl-2 family proteins are essential regulators of apoptosis induced by multiple stimuli that act in part by controlling the status of the mitochondria. We found that two anti-apoptotic Bcl-2 homologues, Bcl-2 and Bcl-X,, were both able to dramatically inhibit difopein. These results argue that the 14-3-3 survival signal acts upstream of Bcl-2 and Bcl-X,. It is likely that difopein can disrupt the 14-3-3-Bad interaction to liberate Bad, which then acts directly on Bcl-2 and Bcl-X,. However, given the large number of 14-3-3 ligands involved in apoptosis, it seems unreasonable that such a simple model can completely account for the cellular effects of 14-3-3. Because phosphorylation of serine or threonine often serves as a signal to induce 14-3-3-ligand interaction, it is possible that 14-3-3-ligand interaction inhibitors would be insensitive to kinase activity. This was tested for a key survival signalling kinase, Akt/PKB, which promotes survival in part through phosphorylation of the 14-3-3 ligands Bad and F K H R L l . Constitutively active Akt/PKB had little effect on difopeininduced apoptosis, despite its robust expression and its ability to decrease the basal level of cell death. Taken together, these data argue that 14-3-3-ligand interactions are important for signal transmission from upstream survival signalling kinases to the core apoptotic mechanisms.
The I 4-3-3 antagonist R I 8 sensitizes tumour cells to cisplatin-mediated cell death
Insufficient induction of apoptosis is now recognized as a hallmark of cancer [40] . We examined the effects of 14-3-3 antagonists in A549 (lung), DU145 (prostate) and HeLa (cervix) cancer cell lines to determine whether they could be effectively killed. Difopein decreased viability in all three lines to varying degrees. Given the ubiquitous nature of 14-3-3, it is likely that difopein may have a broad anti-tumour spectrum. Because conventional anti-neoplastic agents rely on induction of apoptosis for their efficacy, agents that can blunt the overactivation of survival mechanisms may enhance the utility of current anticancer therapies. T o test the possibility that inhibition of 14-3-3-ligand interactions facilitates induction of apoptosis by cytotoxic agents, we examined the effect of R18 on cisplatin-induced cell death. Transfection of COS-7 cells with Myc-R18 prior to cisplatin treatment enhanced the ability of cisplatin to kill cells. When used independently at low levels neither cisplatin nor R18 had a significant effect on viability. However, low-dose cisplatin and R18 in combination were toxic to the cells. This result indicates that R18 may sensitize COS-7 cells to cisplatin-induced death. In addition, it was possible to see similar effects in cisplatin-treated HeLa cells. Inhibition of 14-3-3-ligand interactions could be a useful therapeutic strategy with the potential to improve conventional cancer therapy.
In conclusion, 14-3-3 proteins appear to mediate an essential anti-apoptotic signal in cells. 14-3-3 may promote cell survival in part by binding and inhibiting proapoptotic proteins, such as Bad and A S K l , and in part by enhancing the function of prosurvival proteins. Because many diseases, including cancer, have up-regulated survival machinery, inhibition of 14-3-3-ligand interactions may offer therapeutic opportunities. Our 14-3-3 antagonists that target the same binding site as natural ligands will not only allow us to dissect the function of 14-3-3 in many cellular processes, but may also lead us to novel strategies for the treatment of diseases involving disregulated cell survival.
